{"id":"cc-42344","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3916385","moleculeType":"Small molecule","molecularWeight":"502.67"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CC-42344 works by binding to the SARS-CoV-2 main protease, which is essential for the viral replication. This binding prevents the protease from processing the viral polyprotein, ultimately inhibiting the replication of the virus. As a result, CC-42344 has the potential to treat COVID-19.","oneSentence":"CC-42344 is a small molecule inhibitor of the SARS-CoV-2 main protease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:49:56.228Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19"}]},"trialDetails":[{"nctId":"NCT05202379","phase":"PHASE1","title":"CC-42344 Safety Study in Healthy Participants","status":"COMPLETED","sponsor":"Cocrystal Pharma, Inc.","startDate":"2022-02-11","conditions":"Influenza A","enrollment":80},{"nctId":"NCT06160531","phase":"PHASE2","title":"Influenza Viral Challenge Study of CC-42344 in Healthy Participants","status":"COMPLETED","sponsor":"Cocrystal Pharma, Inc.","startDate":"2023-11-25","conditions":"Influenza A","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Active"],"phase":"phase_2","status":"active","brandName":"CC-42344","genericName":"CC-42344","companyName":"Cocrystal Pharma, Inc.","companyId":"cocrystal-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CC-42344 is a small molecule inhibitor of the SARS-CoV-2 main protease. Used for Treatment of COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}